Szeremeta, A.; Jura-Półtorak, A.; Zoń-Giebel, A.; Olczyk, K.; Komosińska-Vassev, K.
TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. J. Clin. Med. 2022, 11, 4213.
https://doi.org/10.3390/jcm11144213
AMA Style
Szeremeta A, Jura-Półtorak A, Zoń-Giebel A, Olczyk K, Komosińska-Vassev K.
TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. Journal of Clinical Medicine. 2022; 11(14):4213.
https://doi.org/10.3390/jcm11144213
Chicago/Turabian Style
Szeremeta, Anna, Agnieszka Jura-Półtorak, Aleksandra Zoń-Giebel, Krystyna Olczyk, and Katarzyna Komosińska-Vassev.
2022. "TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis" Journal of Clinical Medicine 11, no. 14: 4213.
https://doi.org/10.3390/jcm11144213
APA Style
Szeremeta, A., Jura-Półtorak, A., Zoń-Giebel, A., Olczyk, K., & Komosińska-Vassev, K.
(2022). TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis. Journal of Clinical Medicine, 11(14), 4213.
https://doi.org/10.3390/jcm11144213
